OPEN ACCESS Freely available online

Journal of Cancer Science and Research

Opinion Article

Epigenetic Regulation of Tumour-Associated Macrophages in Pancreatic Ductal Adenocarcinoma

Daniel Kim*

Department of Hematology and Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

DESCRIPTION

Pancreatic ductal adenocarcinoma is a highly aggressive and lethal form of cancer with a dismal five year survival rate. The tumour microenvironment plays a crucial role in disease progression, therapeutic resistance, and immune evasion. Among the cellular components of the microenvironment, tumour associated macrophages are particularly influential due to their ability to modulate immune responses, support tumour growth, and influence angiogenesis. These macrophages are not static; their phenotypic and functional characteristics are shaped by dynamic epigenetic mechanisms, including Deoxyribonucleic Acid (DNA) methylation, histone modifications, and non coding Ribonucleic Acid (RNA) regulation. Understanding the epigenetic regulation of tumour associated macrophages in pancreatic ductal adenocarcinoma is critical for identifying novel therapeutic targets and improving treatment outcomes.

Tumour associated macrophages are recruited to the tumour microenvironment through a combination of chemotactic signals released by cancer cells, stromal cells, and immune components. Once within the tumour milieu, macrophages undergo polarization towards a spectrum of phenotypes ranging from pro inflammatory to immunosuppressive. In pancreatic ductal adenocarcinoma, the majority of tumour associated macrophages exhibit an immunosuppressive phenotype, promoting tumour growth, inhibiting cytotoxic T cell activity, and supporting metastatic spread. Epigenetic mechanisms act as molecular switches that determine the polarization state of macrophages in response to local environmental cues, thereby influencing their functional behavior and contribution to tumour progression.

DNA methylation, the addition of methyl groups to cytosine residues in gene promoter regions, is a key epigenetic mechanism regulating gene expression in tumour associated macrophages. Hypermethylation of promoters associated with pro inflammatory genes can suppress the expression of cytokines and chemokines required for effective antitumour immunity. Conversely, hypomethylation of promoters linked to immunosuppressive and tissue remodeling genes enhances macrophage ability to support tumour growth. These DNA methylation patterns are dynamic and responsive to signals from tumour cells, fibroblasts, and extracellular matrix components, creating a feedback loop that sustains the immunosuppressive microenvironment characteristic of pancreatic ductal adenocarcinoma.

Histone modifications, including acetylation, methylation, and phosphorylation, further modulate macrophage phenotype by altering chromatin accessibility and transcriptional activity. Histone acetylation at promoters of immunosuppressive genes facilitates transcription of interleukins, growth factors, and angiogenic factors, whereas deacetylation of pro inflammatory gene loci reduces antitumour cytokine production. Similarly, histone methylation patterns can either promote or inhibit transcription depending on the specific residue modified. These modifications allow tumour associated macrophages to rapidly adapt to changing microenvironmental conditions, reinforcing tumour survival and immune evasion. Non coding RNAs, including micro RNAs and long non coding RNAs, also contribute to the epigenetic regulation of tumour associated macrophages.

The interaction between epigenetically regulated tumour associated macrophages and other components of the pancreatic ductal adenocarcinoma microenvironment is complex and multifaceted. Macrophages secrete growth factors that enhance tumour cell proliferation, remodel the extracellular matrix to facilitate invasion, and promote angiogenesis to support nutrient delivery. By shaping the microenvironment in this manner, epigenetically programmed macrophages contribute directly to tumour aggressiveness, metastasis, and resistance to conventional therapies.

Recent studies have demonstrated that targeting epigenetic regulators in tumour associated macrophages can alter their phenotype and improve therapeutic outcomes in preclinical models of pancreatic ductal adenocarcinoma. Inhibition of DNA methyl transferases or histone deacetylases can shift macrophages from an immunosuppressive to a pro inflammatory state, enhancing cytotoxic T cell infiltration and activity. Similarly, modulation of non coding RNA networks can

Correspondence to: Daniel Kim, Department of Hematology and Oncology, Dana-Farber Cancer Institute, Boston, MA, USA, E-mail: Daniel456kim@stanford.edu

Received: 20-Aug-2025, Manuscript No. JCSR-25-38979; **Editor assigned:** 22-Aug-2025, PreQC No. JCSR-25-38979 (PQ); **Reviewed:** 29-Aug-2025, QC No. JCSR-25-38979; **Revised:** 05-Sep-2025, Manuscript No. JCSR-25-38979 (R); **Published:** 12-Sep-2025, DOI: 10.35248/ 2576-1447.25.10.642

Citation: Kim D (2025). Epigenetic Regulation of Tumour-Associated Macrophages in Pancreatic Ductal Adenocarcinoma. J Can Sci Res. 10:642.

Copyright: © 2025 Kim D. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

suppress tumour promoting macrophage functions and reduce tumour growth. Combining epigenetic therapies with immune checkpoint inhibitors or standard chemotherapy may provide synergistic benefits, transforming the tumour microenvironment from a protective niche to a hostile environment for tumour survival.

The clinical translation of epigenetic modulation of tumour associated macrophages faces several challenges. The heterogeneity of macrophage populations within pancreatic ductal adenocarcinoma, coupled with the dynamic nature of epigenetic modifications, necessitates precise targeting to avoid off target effects. Biomarker guided approaches to identify patients most likely to benefit from macrophage reprogramming strategies are essential. In addition, the timing and sequencing of epigenetic therapies with other treatment modalities require careful optimization to maximize efficacy and minimize toxicity. Ongoing clinical trials are beginning to evaluate these strategies, offering hope for improved outcomes in a disease that has historically been resistant to conventional treatment.

CONCLUSION

Tumour associated macrophages are central regulators of the pancreatic ductal adenocarcinoma microenvironment, and their behavior is profoundly influenced by epigenetic mechanisms. DNA methylation, histone modifications, and non-coding RNA networks collectively shape macrophage polarization and function, promoting tumour growth, immune evasion, and metastasis. Understanding the epigenetic regulation of tumour associated macrophages provides insights into disease progression and identifies novel therapeutic targets. Strategies aimed at reprogramming macrophages through epigenetic interventions, particularly when combined with immunotherapy or conventional treatment, hold the potential to overcome the inherent therapeutic resistance of pancreatic ductal adenocarcinoma. Continued research in this area is essential to translate these findings into clinically effective therapies that improve survival and quality of life for patients suffering from this devastating disease.